Bioorthogonal Molecules for Controlled Payload Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioorthogonal chemistry lacks efficient bioorthogonal bond-cleavage reactions for controlled release of payloads in vivo, limiting applications in chemical biology and therapeutics, as existing reactions do not meet requirements for rapid reaction rates, near-quantitative payload release, and extended serum stability.
Innovation Solution
Development of bioorthogonal molecules with specific structures, such as those according to Formula I and II, that facilitate rapid and controlled release of leaving groups Z upon interaction with releasing molecules like tetrazines, enabling spatiotemporally controlled release of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If existing bioorthogonal reactions are used, then compatibility with biomolecules is achieved, but reaction rate is insufficient and payload release is not quantitative
Solution Approach 1:
The patent modifies the molecular structure parameters of the bioorthogonal compounds by introducing specific substituents (R1-R6 groups) and functional groups that optimize both reaction rate and payload release completeness. The general formula structures allow for parameter optimization to achieve near-quantitative release while maintaining bioorthogonality.
2Reliability
If existing bioorthogonal reactions are used, then bioorthogonality is maintained, but serum stability is insufficient
Solution Approach 1:
The patent employs parameter changes by incorporating specific stable functional groups and substituent patterns (including electron-withdrawing groups at specific positions) that enhance serum stability and extend the half-life of the bioorthogonal compounds in biological environments while maintaining their reactive properties.
3Ease of operation
If conventional chemical reactions are used for payload release, then simplicity is maintained, but control over spatial and temporal release is insufficient
Solution Approach 1:
The patent segments the bioorthogonal system into distinct components: the bioorthogonal compound (with leaving group Z), the releasing molecule (such as tetrazine), and the payload. This segmentation allows for independent optimization of each component and enables precise control over when and where release occurs through selective interaction between the segmented parts.
Solution Approach 2:
The patent introduces a releasing molecule (such as tetrazine) as an intermediary that triggers the release of the payload from the bioorthogonal compound. This intermediary mechanism provides precise temporal and spatial control over payload release while maintaining the overall simplicity of the reaction system through a well-defined trigger-response relationship.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bioorthogonal molecules enable rapid and quantitative release of therapeutic agents, enhancing the potential for targeted drug delivery and reducing side effects, with improved stability and efficacy in biological environments.
Implementation Method 1
bioorthogonal molecules with specific structures, such as those according to Formula I and II, that facilitate rapid and controlled release of leaving groups Z upon interaction with releasing molecules like tetrazines
Data Source
AI summary
A bioorthogonal molecule can include a molecule having a structure according the above wherein R1-R8 are independently selected from H, a substituted or unsubstituted C1-C4 alkyl or alkylene group, COOH, COOR9, COR9, CONR9R10, CN, CF3, and SO2R9, and where R9 and R10 are independently selected from H and a substituted or unsubstituted C1-C4 alkyl or alkylene group, with the proviso that one of R3-R8 comprises a leaving group, and wherein X is O, S, N, SO, SO2, SR+, Se, PO2−, or NRR′+, and where R and R′ are independently selected from H or a substituted or unsubstituted C1-C4 alkyl or alkylene group.